S92 FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD

边疆 慢性阻塞性肺病 单克隆抗体 相(物质) 计算机科学 医学 免疫学 抗体 内科学 物理 政治学 量子力学 法学
作者
D Singh,P Guller,Fred Reid,Sarah Doffman,Ulla Seppälä,I Psallidas,Rachel Moate,RI Smith,J Kiraga,E Jimenez,Donald E. Brooks,Anne‐Maree Kelly,M. W. Sadiq,C Kell,MG Belvisi,HC Pandya
标识
DOI:10.1136/thorax-2024-btsabstracts.98
摘要

Introduction

FRONTIER-4 (NCT04631016) examined the effect of tozorakimab on lung function in COPD patients with chronic bronchitis on dual- or triple-inhaled maintenance therapy.

Methods

Patients were randomized 1:1 to receive tozorakimab 600 mg or placebo (PBO) s.c. Q4W. The primary endpoint was change in pre-BD FEV1 from baseline to week 12. Secondary outcomes included post-BD FEV1, time-to-first COPDCompEx event and safety.

Results

The ITT population included 135 patients (tozorakimab, n=67; PBO, n=68). Baseline mean (SD)% predicted pre-BD FEV1 was 44.0% (15.2) for tozorakimab; 45.2% (12.9) for PBO. Former smokers comprised 64.2% (n=43) for tozorakimab; 52.9% (n=36) for PBO. Most patients (>88%) had baseline blood eosinophil counts (BEC) <300 cells/μL. Although the primary endpoint was not met, at week 12 tozorakimab numerically improved pre-BD FEV1 vs PBO (LS mean: 24mL [80% CI −15, 63] p=0.216). Greater effects were observed in patients with ≥2 exacerbations in the prior 12 months (LS mean: 69mL [80% CI 9, 130] n=59) and in those with BEC ≥150 cells/μL (LS mean: 82mL [80% CI 26, 138] n=62). Tozorakimab improved post-BD FEV1 vs PBO at week 12 (LS mean: 67mL [80% CI 17, 116] p=0.044). In a time-to-event analysis, tozorakimab numerically reduced risk of COPDCompEx events vs PBO at week 28 (HR=0.79 [80% CI 0.57, 1.11] p=0.186), with greater effect in patients with ≥2 exacerbations in the prior 12 months (HR=0.61 [80% CI 0.37, 1.00]). Numerical improvements in all endpoints presented here were seen in both former and current smokers. Tozorakimab was well tolerated.

Conclusion

Tozorakimab may improve lung function and reduce COPD exacerbations, especially in patients with frequent exacerbation history.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
momo发布了新的文献求助10
1秒前
所所应助科研通管家采纳,获得10
3秒前
SciGPT应助科研通管家采纳,获得10
3秒前
隐形曼青应助科研通管家采纳,获得10
3秒前
我是老大应助科研通管家采纳,获得10
3秒前
3秒前
SYLH应助科研通管家采纳,获得10
3秒前
科研通AI2S应助科研通管家采纳,获得20
3秒前
SYLH应助科研通管家采纳,获得10
3秒前
英姑应助科研通管家采纳,获得10
3秒前
爆米花应助科研通管家采纳,获得10
3秒前
YamDaamCaa应助科研通管家采纳,获得30
3秒前
5秒前
zhui完成签到,获得积分10
6秒前
RESLR完成签到,获得积分10
7秒前
7秒前
7秒前
用户5063899发布了新的文献求助10
7秒前
9秒前
雨的痕迹完成签到,获得积分10
10秒前
Loik发布了新的文献求助10
10秒前
充电宝应助绛川采纳,获得10
10秒前
量子星尘发布了新的文献求助10
12秒前
12秒前
CAOHOU应助sue采纳,获得10
13秒前
13秒前
Loik完成签到,获得积分10
16秒前
16秒前
苗条梦玉发布了新的文献求助10
17秒前
17秒前
17秒前
22秒前
绛川发布了新的文献求助10
23秒前
momo发布了新的文献求助10
24秒前
搜集达人应助潘善若采纳,获得10
24秒前
yyer发布了新的文献求助10
25秒前
实心小墩墩完成签到,获得积分10
27秒前
32秒前
33秒前
香蕉觅云应助su采纳,获得10
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158